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Abstract 
Serum amyloid A protein (SAA) is the plasma precursor for amyloid A protein (AA), the subunit protein in amyloid deposits of 
secondary or reactive amyloidosis. Several forms of acute phase SAA have been identified in human plasma. To elucidate whether one of 
these forms of SAA predominates in the formation of AA amyloid deposits, the amino acid sequence of the subunit protein in six cases of 
reactive amyloidosis was investigated. Minimal heterogeneity was present at the N-terminus as all samples started with residue 1, 2, or 3 
of SAA. The C-terminus, however, was more heterogeneous with the AA protein in each case terminating at multiple sites from residue 
58 to 84 of SAA. Since less than 20% of the AA protein in each case contained sequence past residue 67 of SAA, the sequence and 
recovery of tryptic peptides containing residues 52, 57, and 60 where human SAA1 and 2 differ was used to determine the relative 
amounts of SAA1 and 2 present. One sample contained only SAA1 sequence, four contained approx. 11% or less of SAA2 sequence, and 
the sixth contained 24-33% of SAA2 sequence. Thus, while five of the six AA samples contained both SAA1 and 2, the predominant 
form in all cases was SAAl. In three of the six cases, the protein defensin was isolated along with the AA protein from the fib&. This 
may suggest neutrophil involvement in SAA processing to AA fibrils. 
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1. Introduction 
In secondary or reactive amyloidosis, the major subunit 
protein in amyloid deposits is amyloid A protein (AA). AA 
protein is related to serum amyloid A protein (SAA) 
consisting of approximately the N-terminal three-fourths of 
the SAA protein. In humans, SAA is synthesized mainly in 
the liver, and is an acute phase reactant whose concentra- 
tion in blood where it circulates complexed to HDL in- 
creases several hundred fold as a result of inflammation 
and tissue damage [l]. SAA has been demonstrated to be 
the precursor for the AA protein in amyloid deposits [2]. 
The factors governing the conversion of SAA to AA 
protein and its deposition into amyloid fibrils are un- 
kllOWll. 
In humans, six forms of SAA have been identified by 
amino acid sequence analysis of isolated plasma SAAs. 
* Corresponding author. Fax: + 1 (317) 269 6378. 
SAA1 (Y, 1 p, and ly each consist of 104 residues differing 
in sequence at only two positions (Fig. 1) [3-61. SAAla 
has Val and Ala, SAAlp has Ala and Val, and SAA1 y 
has Ala and Ala at residue 52 and 57, respectively. SAA2a 
is identical to SAAlp at positions 52 and 57, but differs 
with Asn, Leu, Thr, Lys, and Arg at residues 60, 68, 69, 
84, and 90 where the SAAls have Asp, Phe, Phe, Glu, and 
Lys [4,5]. SAA2/3 is identical to SAA2 (Y except for an 
Arg instead of His at residue 71 [4,5]. In addition to these 
104 residue proteins, SAA forms missing either the N- 
terminal Arg or Arg-Ser have been identified in isolated 
SAA preparations [4-71. These five forms of SAA are 
acute phase reactants increasing in serum concentration 
with the acute phase response. The recently identified 
constitutive SAA (C-SAA or SAA41 does not change in 
serum concentration during an acute phase response [8]. 
C-SAA shares approx. 55% identity with the other SAAs 
and exists as a glycosylated and a non-glycosylated species 
in blood [8]. C-SAA is a 112 residue protein, eight residues 
longer than the other human SAAs due to an octapeptide 
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Fig. 1. Amino acid sequence of human acute phase SAAs. The complete 
sequence of SAAla is given and only those residues differing in the 
other SAAs are listed. The sequence of SAA1 (Y is from Refs. [3] and [4], 
SAM/3 from Ref. [3], SAAly from Ref. [6], SAA2.= and 2p from Ref. 
[4]. The arrows denote the peptides expected from a trypsin digest of 
SAAl. SAA2 would yield similar peptides except for Tll. 
insertion between residues 69 and 70 [8]. Such a peptide 
insertion has been found in the same position in the acute 
phase SAAs of dog, cat, horse, cow, and mink [9-121. In 
addition to these characterized SAA proteins, additional 
heterogeneities have been noted in the amino acid se- 
quence of human SAA preparations suggesting that addi- 
tional forms of SAA may exist [7]. 
All of the human SAA forms except for SAAly have 
been identified at the cDNA or genomic level [5,8,13-191. 
A human SAA3 gene whose derived amino acid sequence 
shows approx. 80% identity to SAA has been described 
[20], but no human SAA3 protein product or mRNA has 
been found and DNA sequence data suggest SAA3 is a 
pseudogene [21]. 
In mouse, four SAA genes and one pseudogene have 
been identified [22-241. However, only one form, SAA2, 
is selectively depleted from blood and deposited into amy- 
loid fibrils in experimentally-induced secondary amyloido- 
sis [25,26]. Those results suggest that in mouse an amy- 
loidogenic form of SAA exists. To determine if a similar 
situation exists in man where one of the human SAA 
proteins may be more amyloidogenic, we have investigated 
the primary structure of AA protein in amyloid fibrils from 
six individuals with secondary amyloidosis. Part of this 
study was presented at the VIth International Symposium 
on Amyloidosis in Oslo [27]. 
2. Materials and methods 
2.1. Tissue sources 
Protein CIC was isolated from the spleen of a patient 
with no apparent primary disease, who may have had 
familial Mediterranean fever. Proteins GIB and HEA were 
isolated from the spleens of patients with rheumatoid 
arthritis for 20 and 30 years. Protein JAC was isolated 
from the spleen of a patient who developed osteomyelitis 
from paraplegia 3 years before dying at age 33. Protein 
MUE was isolated from the spleen of a kidney transplant 
patient with glycogen storage disease. Protein WAR was 
isolated from lymph nodes of a 13 year old patient with no 
apparent primary disease whose amyloid deposits were 
resolved with colchicine treatment for 1 year. 
2.2. Isolation of amyloid fibrils 
Fibrils were isolated from tissues by a modification of 
the method of Pras et al. [28] as previously described [9]. 
Briefly, tissues were repeatedly homogenized in 0.9% 
sodium chloride, centrifuged, and the supematant dis- 
carded until the absorbance at 280 nm of the supematant 
was less than 0.075. The remaining pellet was then ho- 
mogenized in water and centrifuged, repeating the proce- 
dure three more times. The water washes and remaining 
pellet were dialyzed against water and lyophilized. 
2.3. Isolation of amyloid subunit protein 
Samples containing amyloid fibrils by Congo red stain- 
ing were suspended in 6 M guanidine hydrochloride, 0.5 
M Tris (pH 8.5) containing 1 mg EDTA/ml, reduced with 
dithiothreitol, and alkylated with iodoacetic acid as previ- 
ously described [9]. The suspension was centrifuged to 
remove insoluble material, and the supematant was frac- 
tionated on a Sepharose CL6B column (2.6 X 90 cm) 
equilibrated and eluted with 4 M guanidine hydrochloride, 
0.05 M Tris (pH 8.2). Eluant was monitored by absorbance 
at 280 nm, and pooled fractions were dialyzed against 
water and lyophilized. 
2.4. SDS-PAGE 
Protein samples were analyzed on SDS-PAGE by the 
procedure of Laemmli [29] or the Tricine system of Schag- 
ger and Von Jagow [30]. 
2.5. Sequence determination 
Protein samples were digested in 0.1 M ammonium 
bicarbonate (pH 8.0) with TPCK trypsin (2% by weight) 
for 2-3 h at room temperature and terminated by lyophili- 
zation [9]. The digests were dissolved in lo-50% acetic 
acid, and peptides were fractionated on a Beckman Ultras- 
phere-ODS column (1 X 25 cm or 0.46 X 25 cm) equili- 
brated with 0.1% TFA in water and eluted with a 0 to 30% 
acetonitrile in 0.1% TFA linear gradient over 60 min and 
then a 30 to 60% acetonitrile gradient over 30 min [9]. 
Eluant was monitored by absorbance at 215 nm. When 
needed, the fractions were further purified on a Vydac 
phenyl column (0.46 X 25 cm) using an acetonitrile gradi- 
ent in 0.1% TFA/water. 
Samples were sequentially degraded in a Beckman 890C 
protein sequencer or an Applied Biosystems 473A protein 
sequencer. For the 89OC, the 0.1 M quadrol program was 
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used for all samples with 3 mg polybrene added to reduce 
extractive losses. The anilinothiazolinone derivatives were 
converted to 2-phenylthiohydantoins by treatment in 1 N 
HCl at 80°C for 10 minutes, and identified by reverse 
phase HPLC using a slight modification of the procedure 
of Zimmerman et al. [31]. Samples on the 473A were 
degraded using the manufacturer’s standard cycles and 
PTH-amino acids were identified by on-line HPLC analy- 
sis. 
3. Results 
Molecular sieve chromatography in guanidine hydro- 
chloride of reduced and alkylated fibrils in all six cases 
resulted in a major subunit protein peak eluting in the 
5000-10000 dalton molecular weight area. Protein HEA 
had an additional peak eluting approximately halfway be- 
tween the major subunit and column volume peaks corre- 
sponding to a size less than 5000 daltons. Upon analysis of 
the pooled peaks by SDS-PAGE, CIC, GIB, and WAR 
showed a broad band corresponding to a molecular weight 
of 6500 to 8500 daltons with some tailing. HEA, JAC, and 
MUE displayed a major band not quite as broad from 6300 
to 7500 daltons with some tailing to 8500 daltons. MUE 
also had a minor band at approx. 9000 daltons. The less 
than 5000 dalton pool from HEA had a major band at 
3000-4000 daltons and a minor band at approx. 7000 
daltons. This 3000-4000 dalton band was also weakly 
present in the HEA, JAC, and MUE subunit protein pools. 
Direct sequence analysis of the subunit protein pools for 
15 cycles yielded N-terminal sequences from SAA. HEA, 
JAC, and MUE were missing the N-terminal Arg of SAA 
and all started with the Ser at residue 2 of SAA as the 
N-terminus. CIC and GIB had 55% and 73%, respectively 
of the subunit protein start with Arg and the remainder 
with Ser as the N-terminus. WAR had 32%, 61%, and 7% 
of the subunit protein start with Arg, Ser, and Phe, respec- 
tively, from residues 1, 2, and 3 of SAA. 
The purified subunit protein pools were digested with 
trypsin and fractionated on a reverse phase HPLC column, 
and peptides were subjected to Edman degradation analy- 
sis. The tryptic peptides expected from SAA are given in 
Fig. 1. While the recoveries based on initial yields from 
sequence analysis of T2 to T9 peptides (N-terminus to 
residue 62) for each protein were similar, the recoveries of 
peptides C-terminal to residue 62 were decreasing. Table 1 
summarizes the peptides C-terminal to residue 46 found in 
each protein and the relative amounts recovered compared 
to total T9 peptides. The yields of TlO peptides varied 
from 36 to 76%, and the yields of Tll peptides from < 1 
to 19% of the total T9 peptides. The lower recoveries of 
TlO and Tll peptides and the partial sequences found 
suggest that the AA proteins are heterogeneous at the 
C-terminus and probably terminate at multiple sites from 
residue 58 to 84 of SAA. This would be consistent with 
Table 1 
Peptides C-terminal to residue 46 identified in trypsin digests and amounts 
recovered relative to total T9 and TS-9 peptides 
Protein % of total T9 and TS-9 peptides 
T9 and T8-9 (#47-62) T10 (#63-67) T11(#68 on) a 
Residues % Residues % Residues % 
CIC #47(48)-59 13% #63-64 3% #68-74 6% 
#47(48)-62 87% #63-67 50% #68-76 7% 
#68-83a 6% 
GIB #47(48)-59 6% #63-64 12% #68-74 4% 
#47(48)-62 94% #63-67 41% #68-76 9% 
HEA #47(48)-58 7% #63-65 11% #68-? <l% 
#47(48)-62 93% #63-67 65% 
JAC #47(48)-58 19% #63-64 2% #68-74 2% 
#47(4&j-59 5% #63-67 51% #68-76 7% 
#47(48)-62 76% #63-68 10% 
MUE #47(48)-59 33% #63-64 8% #68-74 3% 
#47(48)-62 67% #63-65 12% #68-76 8% 
#63-67 46% #68-80 2% 
#68-83 4% 
#68-84 2% 
WAR #47(48)-59 40% #63-65 18% #68-76 12% 
#47(48)-62 60% #63-67 18% 
a AII Tll peptides had SAA1 sequence with Phe, Phe, and His at 
positions 68, 69, and 71 except for the #68-83 peptide of CIC which had 
SAA2a sequence with Leu, Thr, and His at positions 68, 69, and 71. 
the broad bands observed on SDS-PAGE of the proteins. 
All the partial Tll peptides recovered had SAA1 sequence 
except the residue 68-83 peptide from CIC which con- 
tained the SAA2a sequence with L,T, and H at residues 
68, 69, and 71. 
Three of the differences among the acute phase human 
SAAs occur in tryptic peptides T9 and T8-9 at residues 52, 
57, and 60. The other differences occur C-terminal to T9 at 
residues 68, 69, 71, 84, and 90. From the results above, 
these latter positions were absent in the majority of the 
amyloid protein in all six cases while the recovery of T9 
peptides was similar to that of peptides N-terminal to T9. 
Thus, we used the sequences and recovered amounts of T9 
peptides to quantitate the relative amounts of SAA1 and 2 
in the amyloid fibrils. Table 2 summarizes the sequences 
and recoveries of T9 peptides from the six samples. While 
all proteins contained T9 peptides from SAA1 with V, A, 
and D at residues 52, 57, and 60, five contained peptides 
from SAA2 with A, V, and N at these positions. All also 
contained partial T9 peptides ending at residue 58 or 59 
from SAA1 with V and A at residues 52 and 57. Three 
contained peptides ending at position 58 or 59 with A and 
V at residue 52 and 57 which could be derived from 
1 10 20 30 
ACYCRIPACIAGERRYGTCIYQGRLWAFCC 
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Fig. 2. Amino acid sequence of human defensin I from Ref. [32]. Arrows 
denote the tryptic peptides Tom defensin I. Defensin II consists of 
residues 2 to 30 of defensin I missing the N-terminal Ala. Defensin III 
has an identical sequence except for an Asp instead of Ala at residue 1. 
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Table 2 
Relative amounts of SAA1 and 2 sequences in T9 and T8-9 peptides 
Protein % of total T9 and T8-9 peptides 
CIC 
GIB 
HEA 
JAC 
MUE 
WAR 
Partial T9 and T8-9 Complete T9 and T8-9 %SAA2 %SAA2 
V&A@#52&57 A&V@#S2&57 V,A,&D@#52,57,60 A,V,N@#52,57,60 A&V@#52&57 A,V,N@#52,57,60 
4% 9% 63% 24% 33% 24% 
6% 86% 8% 8% 8% 
7% 82% 11% 11% 11% 
24% 76% 0% 0% 
32% 1% 65% 2% 3% 2% 
33% 7% 56% 4% 11% 4% 
SAAlp or SAA2. If these are from SAA2, then the 
maximal total SAA2 is approx. 33% for CIC, 11% for 
HEA and WAR, 8% for GIB, 3% for MUE, and 0% for 
JAC. If the partial T9 sequence is from SAAlp, then the 
minimal amount of SAA2 is approx. 24%, 2%, and 4% for 
CIC, MUE, and WAR, respectively, while the others are 
the same. 
Three of the trypsin digested proteins contained pep- 
tides whose sequences were not from SAA but were 
identical to defensin [32]. The tryptic peptides expected 
from defensin, Fig. 2, were identified in the digests of 
proteins HEA, JAC, and MUE. The molar amounts of 
these peptides recovered were approx. 5 to 20% of the AA 
protein. Direct sequence analysis of these subunit pools 
yielded a minor sequence identical to that of defensin at 
approx. a 17%, 6%, and 4% molar level of AA sequence in 
HEA, JAC, and MUE respectively. Sequence analysis of 
the less than 5000 dalton pool from HEA yielded the 
sequence of defensin at approx. a lo-fold greater molar 
amount than that of AA protein. Approx. 80% started with 
Ala at residue 1 (defensin I), while approx. 20% started 
with Cys at residue 1 (defensin II). The molecular weight 
of defensin, approx. 3500 daltons, is consistent with the 
size of the major SDS-PAGE band in the less than 5000 
dalton pool of HEA from Sepharose CL6B. This band was 
also weakly present in the subunit protein pools of HEA, 
JAC, and MUE where tryptic peptides from defensin were 
found. 
4. Discussion 
All six of the AA protein samples displayed broad 
bands when analyzed by SDS-PAGE suggesting that the 
proteins were heterogeneous in size. Minimal N-terminal 
heterogeneity was found with three preparations having 
only the Ser of residue 2 of SAA, two having the Arg and 
Ser of residues 1 and 2, and one having the Arg, Ser, and 
Phe of residues 1, 2, and 3 as N-termini. Similar N-termi- 
nal heterogeneity has been observed in previously charac- 
terized AA proteins [33-431. The C-terminus was more 
heterogeneous in all preparations. The decreased recovery 
of tryptic peptides TlO and Tll compared to T9 and the 
identification of partial tryptic peptides suggested that 
proteins terminating at multiple positions in this region 
were present. The samples contained significant amounts 
of peptides terminating at residues 58 or 59, 64 or 65, and 
74 or 76. One or two also had peptides ending at residues 
68, 80, 83, and 84. It may also be possible that some of the 
proteins ended at residues 62 and 67, trypsin cleavage 
sites, since the total amount of TlO peptides recovered was 
less than that of intact T9 peptide and the total amount of 
Tll peptides recovered was less than that of intact TlO 
peptide. While AA proteins with some of these C-termini 
have been described previously [34-37,40,43], those ter- 
minating at residues 58, 59, 65, 68, 74, 80, or 84 have not. 
While minor amounts of AA protein were found to 
terminate at residue 76, the most frequently reported C- 
terminus, the majority in each case were shorter terminat- 
ing by residue 67. The fact that five of these fibril prepara- 
tions were isolated from spleen might suggest that the 
shorter length AA protein may be unique to spleen amy- 
loid. However, similar short length AA proteins were also 
isolated from lymph nodes (WAR). In addition, AA pro- 
teins ending before residue 67 have been isolated by others 
from kidney [41], liver [36], and thyroid [39] as well as 
spleen [33,38]. Thus the shorter length AA proteins are not 
a unique feature of spleen amyloid. 
The recovery of tryptic peptides C-terminal to residue 
67 was less than 20% that of peptides N-terminal to 
residue 62 in all six cases. Thus, the majority of the AA 
proteins were missing five of the eight residues where 
SAA1 and 2 differ. In contrast, the recovery of tryptic 
peptide T9 which contains the other three differences 
between SAA1 and 2 was similar to that of peptides 
N-terminal to residue 47. Thus, the sequence and recov- 
ered amount of peptides containing residue 48-62 was 
used to determine the relative amounts of SAA1 and 2 in 
the amyloid. 
While one preparation (JAC) had only SAA1 (Y derived 
sequence, the other five had at least 2-24% of the total 
AA with Ala, Val, and Asn at residues 52, 57, and 60 
derived from SAA2. In three cases, partial tryptic peptides 
with Ala and Val at residues 52 and 57, but missing 
residue 60, were identified which could be derived from 
SAAlp or SAA2. If these were from SAA;?, then the 
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SAA2 derived protein would be 3-33% of the total AA. In 
either case, SAA1 sequence comprised approx. 90% or 
more of the total AA protein in five of the six cases, and 
67-76% in the sixth case. Thus, SAA1 is the major form 
of SAA deposited in these six cases. No tryptic peptides 
from SAAly or constitutive SAA4 were found in any of 
these AA fibrils. 
Several of the previously characterized AA proteins end 
at residue 45 or 50 of SAA, before the region containing 
the residues distinguishing the various SAA forms, and 
thus their precursor SAAs are unknown [33,38,39]. Of 
those extending to residue 64 or beyond, most have se- 
quences consistent with SAA1 (Y [35-37,39-411. Two 
preparations had both Val and Ala at residue 52 but only 
Ala at residue 57 suggesting that some of the AA protein 
was derived from SAA1 y as well as SAA1 (Y [37,39]. One 
partially characterized preparation contained only Val at 
residue 57 while having Asp, Phe, and Phe at residues 60, 
68, and 69 suggesting that the amyloid was derived from 
SAAlp [42]. Only two reports have described AA protein 
derived from SAA2. One of the first characterized AA 
preparations contained sequence derived from SAA2 /3 only 
[34]. A more recent report separated AA protein into two 
fractions, the major fraction derived from SAAly and the 
minor fraction derived from SAA2a [43]. This is the only 
previous description of AA protein derived from SAA1 
and 2 together in amyloid fibrils. While we found SAA1 
and 2 present together in five of six AA preparations, the 
amount of SAA2 was approx. 10% or less in all cases 
except one. Whether such minor amounts were looked for 
or would have been detected in previous AA preparations 
is not known. 
The protein defensin was isolated along with the AA 
subunit protein from three of the six amyloid fibril prepa- 
rations. While two of the preparations containing defensin 
(JAC and MUE) had the lowest content of SAA2 derived 
AA protein, the third preparation (HEA) had the second 
highest SAA2 derived content. Thus, there is no apparent 
correlation between the presence of defensin and content 
of SAA2 derived AA protein in fibrils. The defensins are a 
family of small peptides present in the granules of neu- 
trophils that display antimicrobial and cytotoxic activity by 
disruption or permeabilization of membranes [44]. The 
crystal structure of the molecule shows it is mainly a 
three-stranded antiparallel P-sheet that includes 60% of 
the residues, and forms a dimer such that the P-sheet 
extends across the dimer interface to form a six-stranded 
sheet [45]. The presence of defensin in only some of the 
amyloid fibrils would argue against it being a normal 
constituent of amyloid, but may suggest that the site of 
proteolytic processing of SAA to AA could occur in 
neutrophils. The P-sheet structure of defensin may favor 
its interaction with the fibril and result in its association 
with the amyloid. Neutrophils and neutrophil proteases 
have been shown to totally degrade SAA in vitro [46,47]. 
The proteolytic pathway in vivo may be different resulting 
in partial degradation of SAA, or other factors may protect 
portions of SAA from complete degradation yielding AA 
size peptides leading to fibril formation. 
Acknowledgements 
This work was supported by Veterans Affairs Medical 
Research (MRIS 583-0888), and grants from United States 
Public Health Service, RR-00750, NIDDK-42657, 
NIDDK-42111, NIA-10608, NIAMS-20582, The Arthritis 
Foundation, and The Marion E. Jacobson Fund. 
References 
[I] Kushner, I. (1982) Ann. NY Acad. Sci. 389, 39-48. 
[2] Husebekk, A., Skogen, B., Husby, G. and Marhaug, G. (1985) 
Stand. .I. Immunol. 21, 283-287. 
[3] Parmelee, D.C., Titani, K., Ericsson, L.H., Eriksen, N., Benditt, E.P. 
and Walsh, K.A. (1982) Biochemistry 21, 3298-3303. 
[4] Dwulet, F.E., Wallace, D.K. and Benson, M.D. (1988) Biochemistry 
27, 1677-1682. 
[51 Kluve-Beckerman, B., Dwulet, F.E. and Benson, M.D. (1988) .I. 
Clin. Invest. 82, 1670-1675. 
[6] Baba, S., Takahashi, T., Kasama, T., Fujie, M. and Shirasawa, H. 
(1993) Arch. Biochem. Biophys. 303, 361-366. 
171 Sletten, K., Marhaug, G. and Husby, G. (1983) Hoppe-Seyler’s Z. 
Physiol. Chem. 364, 103991046. 
[8] Whitehead, AS., deBeer, M.C., Steel, D.M., Rits, M., Ielias, J.M., 
Lane, W.S. and deBeer, F.C. (1992) J. Biol. Chem. 267, 3862-3867. 
191 Kluve-Beckerman, B., Dwulet, F.E., DiBartola, S.P. and Benson, 
M.D. (1989) Comp. Biochem. Physiol. [B] 94, 175-183. 
[lo] Sletten, K., Husebekk, A. and Husby, G. (1989) Stand. J. Immunol. 
30, 117-122. 
[ll] Benson, M.D., DiBartola, S.P. and Dwulet, F.E. (1989) J. Lab. Clin. 
Med. 113, 67-72. 
[12] Marhaug, G., Husby, G. and Dowton, S.B. (1990) J. Biol. Chem. 
265, 10049-10054. 
[13] Sipe, J.D., Colten, H.R., Goldberg, D., Edge, M.D., Tack, B.F., 
Cohen, A.S. and Whitehead, AS. (1985) Biochemistry 24, 2931- 
2936. 
[14] Kluve-Beckerman, B., Long, G.L. and Benson, M.D. (1986) 
Biochem. Genet. 24, 795-803. 
[15] Woo, P., Sipe, J., Dinarello, C.A. and Colten, H.R. (1987) J. Biol. 
Chem. 262, 15790-15795. 
[16] Steinkasserer, A., Weiss, E.H., Schwaeble, W. and Linke, R.P. 
(1990) B&hem. J. 268, 187-193. 
[17] Betts, J.C., Edbrooke, M.R., Thakker, R.V. and Woo, P. (1991) 
Stand. J. Immunol. 34, 471-482. 
1181 Watson, G., Coade, S. and Woo, P. (1992) Stand. J. Immunol. 36, 
703-712. 
[191 Steel, D.M., Sellar, G.C., Uhlar, C.M., Simon, S., deBeer, F.C. and 
Whitehead, A.S. (1993) Genomics 16, 447-454. 
[20] Sack, G.H., Jr. and Talbot, C.C., Jr. (1989) Gene 84, 509-515. 
[21] Kluve-Beckerman, B., Drumm, M.L. and Benson, M.D. (1991) 
DNA Cell. Biol. 10, 651-661. 
[22] Yamamoto, K.-I. and Migita, S. (1985) Proc. Natl. Acad. Sci. USA 
82, 2915-2919. 
[23] Lowell, C.A., Potter, D.A., Stearman, R.S. and Morrow, J.F. (1986) 
J. Biol. Chem. 261, 8442-8452. 
1241 deBeer, M.C., Kindy, M.S., Lane, W.S. and deBeer, F.C. (1993) J. 
Biol. Chem. 269, 4661-4667. 
1251 Hoffman, J.S., Ericsson, L.H., Eriksen, N., Walsh, K.A. and Bcnditt, 
E.P. (1984) J. Exp. Med. 159, 641-646. 
86 J.J. Liepnieks et al. /Biochimica et Biophysics Acta 1270 (1995) 81-86 
[26] Meek, R.L., Hoffman, J.S. and Bend&, E.P. (1986) J. Exp. Med. [37] Moyner, K., Sletten, K., Husby, G. and Natvig, J.B. (1980) Stand. J. 
163, 499-510. Immunol. 11, 549-554. 
[27] Liepnieks, J.J., Leagre, C., Kluve-Beckerman, B. and Benson, M.D. 
(1991) in Amyloid and Amyloidosis 1990 (Natvig, J.B., Form, O., 
Husby, G., Husebekk, A., Skogen, B., Sletten, K. and Westermark, 
P., eds.), pp. 511-514, Kluwer Academic Publishers, Dordrecht, 
The Netherlands. 
[38] Westermark, G.T., Westermark, P. and Sletten, K. (1987) Lab. 
Invest. 57, 57-64. 
[39] Prelli, F., Pras, M. and Frangione, B. (1987) Biochemistry 26, 
8251-8256. 
[28] Pras, M., Schubert, M., Zucker-Franklin, D., Rimon, A. and Franklin, 
E.C. (1968) J. Clin. Invest. 47, 924-933. 
[29] Laemmli, U.K. (1970) Nature 227, 680-685. 
[30] Schagger, H. and von Jagow, G. (1987) Anal. Biochem. 166, 
368-379. 
[40] Skinner, M., Pinnette, A., Travis, W.D., Shwachman, H. and Cohen, 
A.S. (1988) J. Lab. Clin. Med. 112, 413-417. 
[41] Westermark, G.T., Sletten, K. and Westermark, P. (1989) Stand. J. 
Immunol. 30, 605-613. 
[31] Zimmerman, C.L., Appella, E. and Pisano, J.J. (1977) Anal. 
Biochem. 77, 569-573. 
[32] Selsted, M.E., Ha&g, S.S.L., Ganz, T., Schilling, J.W. and Lehrer, 
RI. (1985) J. Clin. Invest. 76, 1436-1439. 
[33] Ein, D., Kimura, S., Terry, W.D., Magnotta, J. and Glenner, G.G. 
(1972) J. Biol. Chem. 247, 5653-5655. 
[34] Levin, M., Franklin, E.C., Frangione, B. and Pras, M. (1972) J. Clin. 
Invest. 51, 2773-2776. 
[42] Westermark, G.T., Sletten, K., Grubb, A. and Westermark, P. (1990) 
Am. J. Pathol. 137, 377-383. 
[43] Baba, S., Takahashi, T., Kasama, T. and Shirasawa, H. (1992) 
Biochim. Biophys. Acta 1180, 195-200. 
[44] Ganz, T., Gelsted, M.E. and Lehrer, R.I. (1990) Eur. J. Haematol. 
44, l-8. 
[45] Hill, C.P., Yee, J., Selsted, M.E. and Eisenberg, D. (1991) Science 
251, 1481-1485. 
[46] Silverman, S.I., Cathcart, E.S., Skinner, M. and Cohen, A.S. (1982) 
Immunology 46, 737-744. 
[35] Sletten, K. and Husby, G. (1974) Eur. J. Biochem. 41, 117-125. 
[36] Sletten, K., Husby, G. and Natvig, J.B. (1976) Biochem. Biophys. 
Res. Commun. 69, 19-25. 
[47] Shephard, E.G., deBeer, F.C., deBeer, M.C., Jeenah, MS., Coetzee, 
G.A. and Van der Westhuyzen, D.R. (1987) Biochem. J. 248, 
919-926. 
